Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
15 hedge funds and large institutions have $974K invested in Pear Therapeutics, Inc. Warrant in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$233K |
| 2 |
SCM
Saba Capital Management
New York
|
+$206K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$81.2K |
| 4 |
OCM
Oribel Capital Management
New York
|
+$68.9K |
| 5 |
SC
Sculptor Capital
New York
|
+$65K |
Top Sellers
PEARW Hedge Fund Activity: Q1 2021 in Review
15 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q1 2021, worth a combined $974K.
Buyers outnumbered sellers: 15 funds opened new PEARW positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $233K.
- 15 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $974K of Pear Therapeutics, Inc. Warrant stock for Q1 2021.
- 15 funds opened new Pear Therapeutics, Inc. Warrant positions in Q1 2021 and 0 closed out, a net change of +15 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q1 2021 was Citadel Advisors, an estimated $233K added.
Based on aggregated 13F filings for Q1 2021.